Overview

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

Status:
Not yet recruiting
Trial end date:
2023-08-31
Target enrollment:
Participant gender:
Summary
A Controlled Clinical Study of TC/PD-1 Inhibitors Combined With anlotinib as First-line Treatment for Advanced ESCC
Phase:
N/A
Details
Lead Sponsor:
Dong Wang
Treatments:
Immune Checkpoint Inhibitors